Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (112)	5/14/2003 11:44:53 AM
From: tuck	Read Replies (1) \| Respond to of 510

Do not know if CIPH has a piece of this. The '02 test that found the markers in the first place used Ciphergen equipment and Correlogic software. Along with BDAL's recent entry in the diagnostic market, it seems as though the proteomics based clinical diagnostics market is attracting more players. >>BETHESDA, Md., May 14 /PRNewswire/ -- Correlogic Systems, Inc., the developer of promising new cancer detection tests that use just a single drop of blood from a patient, has entered into an agreement with Advion BioSciences, a leading provider of mass spectrometry services and products, to explore the use of Advion's NanoMate(TM) System as a component of Correlogic's upcoming ovarian cancer clinical trials. Correlogic's test, called Proteome Pattern Blood Test(SM), scans a drop of blood for protein patterns generated by a mass spectrometer. In February 2002, Correlogic Systems earned international recognition when its joint research with the National Cancer Institute (NCI) and the Food and Drug Administration (FDA) revealed that the Correlogic test successfully detected all of the ovarian cancer patients in a study of 216 women, including cancers that were still in Stage 1. On April 9, 2003, NCI announced that Correlogic, NCI, and FDA scientists have achieved further improved results. The team was able to detect ovarian cancer with 100 percent accuracy -- again identifying all of the cases of ovarian cancer -- but without any false positives. The goal of the Correlogic-Advion research is to determine whether results similar to those published in February 2002 can be replicated on the NanoMate system and thereby employed in the NCI-sponsored clinical trials scheduled to begin soon. According to Jack Henion, president of Advion, "The NanoMate 100 is an ideal tool for consideration in Correlogic's clinical trials because it is a simple-to-use, automated nanoelectrospray platform that promises to increase the throughput and quality of the analysis." Peter Levine, president and chief executive officer of Correlogic Systems, Inc., indicated that the benefits of greater process automation, efficiency and capacity to handle test demand make Advion's technology a smart choice. "This agreement is about getting the most accessible and accurate ovarian cancer test to every woman who needs it," Levine said. "If the results of our joint research and validation studies confirm what we believe to be the case, the public will benefit enormously." Advion and Correlogic have already begun the research and validation process, and will detail results to date at the American Society of Mass Spectrometry Conference to be held June 8, 2003. About Correlogic Systems, Inc. Correlogic Systems, Inc. is a Bethesda, Maryland-based BioIT company that has developed patent-pending pattern recognition and pattern discovery software and processes with a wide variety of applications for bio-marker discovery, disease detection, and new drug discovery. The technology's first application has been in the field of proteomics -- the study of human proteins -- with concentration on the early detection of prostate, ovarian, breast and other cancers. The Correlogic Proteome Pattern Blood Test(SM) is a cutting edge approach to disease detection, using Correlogic's proprietary hidden patterns technology including ProteomeQuest(TM) and ProteomeDx(TM). Correlogic has entered into licensing agreements with Quest Diagnostics, Inc. (NYSE: DGX - News) and Laboratory Corporation of America (NYSE: LH - News) for the commercialization of Correlogic's ovarian cancer protein pattern blood test. Visit Correlogic Systems at www.correlogic.com. << Cheers, Tuck